Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction
The purpose of this study is to assess the efficacy and safety of patients who receive concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2 negative adenocarcinoma at gastroesophageal junction.
Gastroesophageal Junction Adenocarcinoma
DRUG: Apatinib Capecitabine Oxaliplatin|DRUG: Capecitabine Oxaliplatin
The pathological complete response rate(pCR), The lesion disappeared completely by pathology, [ Time Frame: within 3 weeks after surgery ]|Disease-free survival(DFS), Baseline to measured date of recurrence or death from any cause, [ Time Frame: 3 year ]
Objective response rate (ORR), Baseline to measured stable disease, [ Time Frame: Preoperative ]|Disease Control Rate（DCR）, Baseline to measured disease progression, [ Time Frame: Preoperative ]|R0-resection rate, There was no residual by the microscope, [ Time Frame: within 3 weeks after surgery ]|Overall survival (OS), Baseline to measured date of death from any cause, [ Time Frame: 3years ]
The purpose of this study is to assess the efficacy and safety of patients who receive concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2 negative adenocarcinoma at gastroesophageal junction.